ASH 2022 | CIMON: efficacy of MaaT033 in restoring gut microbiota in patients with AML after chemotherapy

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, describes the rationale, design, and results of the CIMON trial (NCT04150393), which investigated the tolerability, safety and efficacy of MaaT033, an oral capsule containing lyophilized pooled full ecosystem fecal microbiota, in restoring gut microbiota of patients with acute myeloid leukemia (AML) having undergone intensive chemotherapy. The Phase II dose escalation trial demonstrated that the capsule is safe, with no serious adverse events recorded, and also showed it was effective, particularly in patients who received three MaaT033 capsules per day. The capsule also helped maintain high microbiome diversity after induction chemotherapy. This product is expected to be evaluated in a clinical trial to investigate if the MaaT033 capsule can be used before or after allogeneic hematopoeitic stem cell transplantation (alloHSCT) to improve patient outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.